Company profile: Nufabrx
1.1 - Company Overview
Company description
- Provider of blemish-fighting pillowcases hand-crafted from natural bamboo fibers and infused with natural ingredients and clinically proven natural remedies for antibacterial, antimicrobial benefits during sleep; and pain-relieving compression sleeves (knee, ankle, wrist, calf, arm, lower leg) combining medicine with compression for 150+ hours of use.
Products and services
- Pain Relieving Medicine + Compression Ankle Sleeve: A medical-grade ankle sleeve merging compression with pain-relieving medicine, designed for 150+ hours of use
- Pain Relieving Medicine + Compression Knee Sleeve: A clinical-grade knee sleeve combining compression with pain-relieving medicine, engineered for 150+ hours of use
- Pain Relieving Medicine + Compression Wrist Sleeve: An ergonomic wrist sleeve integrating compression with pain-relieving medicine, built for 150+ hours of continuous use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nufabrx
Dogwood Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage antiviral therapies targeting fibromyalgia and Long COVID, including IMC-1, a fixed-dose combination of famciclovir and celecoxib designed to suppress herpes virus replication and reduce fibromyalgia symptoms, and IMC-2, a combination of valacyclovir and celecoxib developed to manage Long COVID-related fatigue, sleep issues, and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dogwood Therapeutics company profile →
Heron Therapeutics
HQ: United States
Website
- Description: Provider of polymer-based pharmaceuticals for acute and oncology care, offering therapies to reduce postsurgical pain and prevent nausea and vomiting from chemotherapy and surgery. Products include SUSTOL (5-HT3 antagonist), CINVANTI (IV NK1 antagonist), ZYNRELEF (bupivacaine + meloxicam), and APONVIE (IV NK1 antagonist), plus Acute Care Solutions and Oncology Care Solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Heron Therapeutics company profile →
NuPathe
HQ: United States
Website
- Description: Provider of specialty pharmaceutical solutions for diseases of the central nervous system, including neurological and psychiatric disorders, with a lead product candidate, NP101, an active, single-use transdermal sumatriptan patch in development for the treatment of migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuPathe company profile →
NeuroCycle Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on sub-type selective GABA-A modulation, including a lead candidate (NCT10004) that selectively targets a newly identified mechanism of action to reduce itch to near-baseline levels across models, including allergic and contact dermatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroCycle Therapeutics company profile →
NeuroMetrix
HQ: United States
Website
- Description: Provider of medical devices for the detection, diagnosis, monitoring, and treatment of neurological complications of diabetes, including diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). Products include DPNCheck, a point-of-care sural nerve conduction test; Quell Fibromyalgia, a wearable neurostimulation device; and ADVANCE System, a platform to screen and confirm median nerve entrapment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroMetrix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nufabrx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nufabrx
2.2 - Growth funds investing in similar companies to Nufabrx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nufabrx
4.2 - Public trading comparable groups for Nufabrx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →